JPRN-UMIN000023621
Completed
Phase 2
A phase II study on the feasibility and efficacy of preoperative chemoradiotherapy with S-1 for locally advanced rectal cancer - A phase II study on the feasibility and efficacy of preoperative chemoradiotherapy with S-1 for locally advanced rectal cancer
Department of Surgery Kindai University Faculty of Medicine0 sites42 target enrollmentAugust 15, 2016
Conditionsrectal cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- rectal cancer
- Sponsor
- Department of Surgery Kindai University Faculty of Medicine
- Enrollment
- 42
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •\# Distant metastases \# Cerebrovascular disease (CVD) with paralytic symptoms or prior CVD within one year. \# Symptomatic or actively treated cardiac disorders. Or prior cardiac disorder within one year. \# Cancerous fluid on diagnostic imaging. \# Prior chemotherapy or pelvic irradiation for malignancy. \# Other cancer diagnosis within the past 5 years (including colorectal cancer). \# Interstitial pneumonia or fibroid lung. \# Uncontrolled diabetes mellitus. \# Uncontrolled hypertension \# Ileus (cases with diverting stoma are eligible). \# Uncontrolled diarrhea. \# Pregnant, nursing or no intention to contraception. \# Those considered inappropriate for participation in this trial.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin*s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHLlymphoma10025320NL-OMON36830HOVO60
Active, not recruiting
Not Applicable
Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation - HOVON 80 NHrelapsed B cell lymphomaMedDRA version: 8.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaEUCTR2006-002141-37-NLHOVON foundation35
Active, not recruiting
Not Applicable
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHLMedDRA version: 14.1Level: PTClassification code 10003902Term: B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10003903Term: B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2006-007083-28-NLHOVON foundation60
Recruiting
Phase 2
A phase II study to evaluate the effectiveness of S-1 + Cetuximab for patients with advanced/recurrent colon cancer who cannot undergo intensive therapyadvanced/recurrent colon cancer patients with RAS wild-type tumors who cannot undergo intensive therapyJPRN-UMIN000018484HO HOKKAIDO CANCER CENTER Division of Gastroenterology57
Active, not recruiting
Not Applicable
A Pilot Phase II Study for the evaluation of efficacy and tolerability of Gammaidroxybutyrate (ALCOVER) administered by oral route as add on treatmant in patients affected by DYT 11 Myoclonic Dystonia. - NDEUCTR2006-001039-23-ITISTITUTO NEUROLOGICO CARLO BESTA